Curcumin
Useful mainly for adults with osteoarthritis seeking a well-tolerated NSAID-adjacent option, or with elevated inflammatory markers.
Quick decision guide
May help most
Adults with osteoarthritis seeking a well-tolerated NSAID-adjacent option, or with elevated inflammatory markers
Common dosing range
500–1,500 mg/day of a bioavailability-enhanced formulation; 500–2,000 mg/day plain curcumin with 5–10 mg piperine
When to expect effects
4–8 weeks for anti-inflammatory and pain effects
Watch out for
Poor bioavailability of plain curcumin; must use enhanced formulation or piperine; rare drug-induced liver injury at high doses; avoid in pregnancy and with anticoagulants
What is it
Curcumin is the most studied bioactive compound found in turmeric (Curcuma longa), a bright-yellow polyphenol that constitutes roughly 2 to 9 percent of dried turmeric rhizome. It is responsible for most of turmeric's anti-inflammatory and antioxidant effects in research settings.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
osteoarthritis pain and function Good Evidence | Comparable to ibuprofen in some trials; effect size is modest to moderate | Adults with mild-to-moderate knee osteoarthritis, especially those who cannot tolerate NSAIDs | 4–8 weeks |
inflammatory biomarkers (CRP, IL-6) Good Evidence | Significant reductions in CRP, IL-6, TNF-alpha in meta-analyses | Adults with elevated inflammatory markers associated with chronic disease | 4–8 weeks |
depression (adjunct treatment) Limited Evidence | Modest symptom reduction in small RCTs versus placebo | Adults with mild-to-moderate depressive disorder as an adjunct to standard care | 4–8 weeks |
ulcerative colitis maintenance Limited Evidence | Reduced relapse rate when added to standard therapy in small trials | Adults with quiescent ulcerative colitis on mesalamine maintenance therapy | Weeks to months |
osteoarthritis pain and function
- Effect
- Comparable to ibuprofen in some trials; effect size is modest to moderate
- Best fit
- Adults with mild-to-moderate knee osteoarthritis, especially those who cannot tolerate NSAIDs
- Time
- 4–8 weeks
inflammatory biomarkers (CRP, IL-6)
- Effect
- Significant reductions in CRP, IL-6, TNF-alpha in meta-analyses
- Best fit
- Adults with elevated inflammatory markers associated with chronic disease
- Time
- 4–8 weeks
depression (adjunct treatment)
- Effect
- Modest symptom reduction in small RCTs versus placebo
- Best fit
- Adults with mild-to-moderate depressive disorder as an adjunct to standard care
- Time
- 4–8 weeks
ulcerative colitis maintenance
- Effect
- Reduced relapse rate when added to standard therapy in small trials
- Best fit
- Adults with quiescent ulcerative colitis on mesalamine maintenance therapy
- Time
- Weeks to months
Evidence for 4 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
osteoarthritis pain and function
Disease adjunctMultiple RCTs and meta-analyses show curcumin supplementation (typically 500–2,000 mg/day with enhanced bioavailability) significantly reduces pain and improves function in knee osteoarthritis compared to placebo. Some head-to-head trials show effect sizes comparable to low-dose ibuprofen, with better GI tolerability. Most trials are under 4 months; long-term data are limited.
Bottom line: Reasonably well-evidenced for osteoarthritis pain relief; an appealing option for those with NSAID intolerance.
inflammatory biomarkers (CRP, IL-6)
Biomarker supportMeta-analyses of RCTs consistently show curcumin supplementation reduces circulating CRP, IL-6, and TNF-alpha in individuals with elevated baseline inflammation. These are biomarker changes; whether they translate to reduced clinical events (cardiovascular disease, cancer progression) has not been demonstrated in outcome-level trials. NF-kB and COX-2 inhibition are the proposed mechanisms.
Bottom line: Consistent biomarker-level anti-inflammatory effect; clinical outcome benefit beyond symptom relief not established.
depression (adjunct treatment)
Disease adjunctSmall RCTs (n = 50–100) show statistically significant reductions in depression and anxiety symptom scores with curcumin (500–1,000 mg/day) versus placebo over 6–8 weeks. Effect sizes are modest, trials are short, and most exclude severe depression. Proposed mechanisms include monoamine modulation and neuroinflammation reduction. Evidence is not sufficient to recommend as monotherapy.
Bottom line: Preliminary evidence as an adjunct for mild-to-moderate depression; not adequate for use as monotherapy.
ulcerative colitis maintenance
Disease adjunctA small RCT found that curcumin added to mesalamine maintenance therapy significantly reduced ulcerative colitis relapse rate compared to placebo over 6 months. Additional small studies support this finding. Evidence is limited by small sample sizes and short duration. Curcumin should not replace standard IBD therapy.
Bottom line: Promising adjunctive role for UC maintenance; evidence base is small and should not displace standard treatment.
How it works
How to take it
What to track
5 commercial forms
Compare the main delivery options and what they’re best suited for.
Curcumin 95 percent extract
Standard concentrated curcumin. Effective only when paired with piperine or another bioavailability enhancer.
Concentrated curcuminoids but low absorption; needs enhancement.
Curcumin + piperine (BioPerine)
Most common cost-effective formulation. Note piperine also affects metabolism of many drugs.
Piperine inhibits curcumin glucuronidation, raising plasma curcumin by approximately 2000 percent.
Meriva (curcumin phytosome)
Well-studied phytosomal formulation. Lower dose for equivalent effect.
Curcumin bound to phosphatidylcholine; 29-fold higher absorption than plain curcumin.
BCM-95 (Curcugreen)
Used in many positive trials. Includes natural turmeric oils for absorption enhancement.
Combined with turmeric essential oils; 7-fold higher absorption than plain curcumin.
Theracurmin (nanoparticle)
Japanese pharmaceutical-grade format. Used in multiple positive trials.
Nanoparticle dispersion in colloidal water; 27-fold higher absorption than plain curcumin.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Rare drug-induced liver injury (DILI) reported with high-bioavailability curcumin formulations — monitor liver enzymes with long-term high-dose use
Who should avoid it
- Pregnant women (medicinal doses are contraindicated; culinary turmeric is fine)
- People with gallstones or biliary obstruction
- People on warfarin, clopidogrel, DOACs, or NSAIDs without prescriber coordination
- People scheduled for surgery within 2 weeks (antiplatelet effects)
Pregnancy & breastfeeding
Culinary turmeric is safe in pregnancy; medicinal curcumin doses are contraindicated due to potential uterine stimulant effects.
Interactions
Curcumin inhibits platelet aggregation and may enhance anticoagulant effects, raising bleeding risk; INR monitoring required
Curcumin and piperine (in combination formulations) inhibit CYP enzymes, potentially raising blood levels of many medications
Curcumin has modest glucose-lowering activity; may compound hypoglycemic effects of insulin and sulfonylureas
Curcumin has theoretical interactions with chemotherapy through CYP modulation and oxidative pathway effects; coordinate with oncologist
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance — a complement to the narrative section above.
Beneficial pairs (7)
+ piperine
synergyPiperine (black pepper extract) substantially increases how much curcumin your body absorbs.
+ boswellia
synergyCurcumin and boswellia act on complementary anti-inflammatory pathways (NF-kB/prostaglandins and 5-LOX/leukotrienes), and a randomized placebo-controlled trial found the combination eased knee osteoarthritis symptoms more than curcumin alone.
+ ginger
synergyCurcumin and ginger share overlapping anti-inflammatory mechanisms (COX-2 and NF-kB inhibition), with ginger adding 5-LOX blockade that curcumin lacks. The combination is favourable and complementary, with both contributing mild antiplatelet potential worth checking before combining with blood thinners.
+ fat
synergyCurcumin is a lipophilic molecule with very low water solubility, and dietary fat improves its dissolution and incorporation into bile-acid micelles for intestinal absorption. Taking curcumin or turmeric with a fat-containing meal, and using lipid-based formulations, raises its plasma exposure compared with intake on an empty stomach.
Protocols featuring Curcumin
Evidence-backed routines where Curcumin plays a role.
Systemic Inflammation Support
longevity
Chronic low-grade systemic inflammation (sometimes called "inflammaging") is a unifying mechanism behind cardiovascular disease, type 2 diabetes, neurodegeneration, autoimmune conditions, and accelerated aging. Unlike acute inflammation (which is necessary and beneficial), chronic inflammation drives tissue damage over years. Measurable markers include hsCRP, IL-6, TNF-alpha, fibrinogen, and homocysteine. This stack targets chronic inflammation through complementary mechanisms: curcumin (NF-kB and COX-2 inhibition with the bioavailability problem solved by phytosome forms), omega-3 EPA (shifts eicosanoid production toward less inflammatory series-3), quercetin (mast cell stabilization and NF-kB modulation), and boswellia (5-LOX inhibition through a distinct pathway). This is distinct from Joint Health & Mobility (osteoarthritis-specific) and Daily Calm (stress-driven). For systemic inflammation, the upstream causes — visceral fat, ultra-processed food intake, chronic stress, poor sleep, sedentary lifestyle — matter more than supplements. The stack is a complementary layer.
Joint Health & Mobility
recovery
Joint discomfort is one of the most universal aging symptoms — and one of the most over-supplemented categories in the entire industry. The literature for glucosamine and chondroitin is genuinely mixed: some trials show modest pain and function improvements in moderate osteoarthritis; others find no effect over placebo. Omega-3 has more consistent evidence for inflammatory joint pain. Curcumin (with appropriate bioavailability enhancement) has rapidly accumulating trial evidence comparable to NSAIDs in mild-to-moderate osteoarthritis. UC-II (undenatured type II collagen) has small but clean trials for knee osteoarthritis. This stack is for everyday joint maintenance and mild-to-moderate osteoarthritis — not a substitute for orthopedic care of serious joint disease.
Autoimmune Foundation
autoimmune
Autoimmune diseases affect roughly 24 million Americans across 80+ conditions: rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease (Crohn''s, UC), psoriasis, Hashimoto''s, type 1 diabetes, celiac, Sjögren''s, and dozens more. They share core pathology: the immune system mistakenly attacks the body''s own tissues, driven by genetic predisposition + environmental triggers (infections, gut microbiome dysbiosis, stress, certain medications, sometimes specific exposures). The modern treatment revolution is biologic therapy (DMARDs: methotrexate, sulfasalazine; biologics: adalimumab, infliximab, etanercept, secukinumab, dupilumab; small molecules: tofacitinib, etc.) — these are genuinely transformative for moderate-to-severe disease. This protocol is a FOUNDATIONAL baseline for adults with an autoimmune diagnosis — NOT a substitute for proper rheumatology, gastroenterology, neurology, or endocrinology care. It targets the universal anti-inflammatory and immune-modulating pathways that affect every autoimmune patient: vitamin D (where deficiency is strongly associated with autoimmune disease activity), omega-3 EPA (anti-inflammatory eicosanoid shift), curcumin (NF-kB inhibition), NAC (glutathione support for oxidative stress), and vitamin K2 (mineral metabolism and growing evidence for inflammatory modulation). CRITICAL: Beware "autoimmune cure" marketing. There''s a substantial wellness-industry ecosystem promising that diet, supplements, or "leaky gut protocols" can reverse autoimmune disease. The honest evidence: lifestyle + supplements measurably reduce disease activity and symptom severity but do NOT replace immunomodulator therapy in moderate-to-severe disease. Don''t stop your DMARD or biologic based on supplement marketing.
RA & Joint Autoimmune
autoimmune
Rheumatoid arthritis affects roughly 1.3 million Americans; psoriatic arthritis another 1 million; ankylosing spondylitis around 250,000. Together with the smaller seronegative spondyloarthropathies they form the family of joint-dominant autoimmune diseases — seropositive (RF, anti-CCP) or seronegative — where the immune system attacks synovium, entheses, and cartilage. Untreated, the consequences are joint destruction, deformity, disability, and significant excess cardiovascular and lung morbidity. The modern standard of care is dramatically better than it was 25 years ago: DMARDs (methotrexate first-line, sulfasalazine, leflunomide, hydroxychloroquine), biologics (anti-TNF: adalimumab, etanercept, infliximab; IL-6: tocilizumab, sarilumab; B-cell: rituximab; T-cell co-stim: abatacept), and small-molecule JAK inhibitors (tofacitinib, upadacitinib, baricitinib). The 2021 ACR RA Guideline recommends early aggressive treatment with methotrexate, escalating to biologic or JAK inhibitor if methotrexate is insufficient. This protocol is a COMPLEMENT to — not a substitute for — disease-modifying therapy. The five supplements stacked here target the inflammatory pathways most relevant to joint autoimmunity: omega-3 EPA (eicosanoid shift, the most evidenced supplement in RA), curcumin (NF-kB and COX-2 inhibition, with trial evidence specifically in RA), vitamin D (deficiency strongly linked to disease activity), boswellia (5-LOX inhibition, evidence strongest in osteoarthritis but mechanistically applicable), and ginger (COX/LOX inhibition, modest meta-analytic evidence). Layer this on top of the Autoimmune Foundation protocol for the universal autoimmune baseline. CRITICAL: see a rheumatologist FIRST. Early aggressive treatment with methotrexate (with or without a biologic) is the new standard of care for moderate-to-severe RA. The biologic-era outcomes — remission, no joint damage on imaging, normal function — are dramatically better than the older-generation methotrexate-only outcomes, which themselves were dramatically better than the pre-DMARD era. Do NOT replace methotrexate or a biologic with supplements.
IBD Support (Crohn's & Ulcerative Colitis)
autoimmune
Inflammatory bowel disease (IBD) affects roughly 3 million Americans across two main forms: Crohn''s disease (can involve any segment of the GI tract, transmural inflammation, often complicated by strictures, fistulas, and surgical resections) and ulcerative colitis (continuous mucosal inflammation limited to the colon, with bloody diarrhea and urgency as hallmark symptoms). This is fundamentally different from IBS (irritable bowel syndrome), which is a functional disorder without structural damage. IBD involves chronic, often progressive intestinal inflammation, ulceration, and sometimes systemic complications (uveitis, arthritis, primary sclerosing cholangitis, increased colorectal cancer risk). The modern treatment revolution is biologic and small-molecule therapy: 5-ASAs (mesalamine for UC), corticosteroids (short-term flare control only), immunomodulators (azathioprine, methotrexate), TNF inhibitors (infliximab/Remicade, adalimumab/Humira), integrin antagonists (vedolizumab/Entyvio), IL-12/23 inhibitors (ustekinumab/Stelara, risankizumab/Skyrizi), and JAK inhibitors (tofacitinib, upadacitinib). These are genuinely transformative — biologic-era outcomes have dramatically reduced surgery rates, steroid dependence, and hospitalizations. This protocol is an ADJUNCTIVE supplement layer for adults with an established IBD diagnosis under gastroenterology care — NOT a substitute for proper medical therapy. It targets: nutrient deficiencies common in IBD due to malabsorption and inflammation (vitamin D, iron, B12), gut barrier support (L-glutamine), and inflammation modulation (omega-3 EPA, curcumin). Trial evidence is strongest for curcumin (Lang 2015 — curcumin + mesalamine outperformed mesalamine alone in UC remission) and vitamin D normalization (Ananthakrishnan 2013 — associated with reduced surgery risk in Crohn''s). CRITICAL: Beware "IBD cure" marketing. There is a substantial ecosystem promising that diet alone, supplements alone, or "leaky gut protocols" can reverse IBD. The honest evidence: supplements + diet measurably help but do NOT replace biologics or immunomodulators in moderate-to-severe disease. Stopping a biologic based on supplement marketing is one of the most reliable ways to lose intestinal tissue.
Post-Workout Recovery
recovery
Recovery determines your next training session, not the workout you just finished. The best-evidenced supplemental levers are unglamorous: enough protein to drive muscle protein synthesis, creatine to maintain phosphocreatine stores, and a small set of anti-inflammatory aids for high-volume blocks or competition stretches. This protocol assumes you are training consistently — three or more sessions per week — and want to recover better between them. If you train less, the protein you eat at meals is sufficient.
Psoriasis Support
skin conditions
Psoriasis is a chronic, immune-mediated inflammatory disease affecting 2-3% of adults. The hallmark is accelerated keratinocyte turnover — skin cells replicating every 3-5 days instead of the normal 28-30 — driven by a Th17/IL-23 immune axis. Clinically that shows up as well-demarcated red plaques with silvery scale, classically on the elbows, knees, scalp, and lower back. Psoriasis is not just a skin disease: it carries substantial comorbid risk. Roughly 30% of patients develop psoriatic arthritis, and the cohort as a whole runs higher cardiovascular disease, metabolic syndrome, and depression rates than the general population. Treatment is genuinely multi-modal — topical corticosteroids and vitamin D analogs (calcipotriol) for limited disease, phototherapy for wider involvement, and systemic biologics targeting IL-17 (secukinumab/Cosentyx), IL-23 (risankizumab/Skyrizi, guselkumab/Tremfya, ustekinumab/Stelara), or TNF-alpha (adalimumab/Humira) for moderate-to-severe disease. If you have moderate-to-severe psoriasis — significant body surface area, scalp/genital/palmar-plantar involvement, joint symptoms, or quality-of-life impact — see a dermatologist. The biologics era has been transformative; PASI 90 (90% lesion clearance) is now a realistic goal for most patients, not the exception. Supplements occupy a supportive role: they can blunt systemic inflammation, correct deficiencies that worsen disease activity, and address the cardiometabolic comorbidity burden. They don't replace appropriate dermatologic care for anything beyond mild localized disease.
Endometriosis Support
hormones
Endometriosis affects 10% of reproductive-age women and is one of the most under-diagnosed conditions in medicine — average diagnostic delay is 7-10 years. The pathology involves estrogen-dependent inflammatory lesions outside the uterus, driving severe menstrual pain, pelvic pain, painful intercourse, and infertility. Conventional treatment includes hormonal suppression (continuous oral contraceptives, GnRH analogs) and surgical excision. The supplement category has growing but still preliminary evidence: omega-3 EPA for inflammatory mediator modulation, magnesium for cramping and mood, NAC for lesion size reduction (small trial), and curcumin for inflammation. None of these replace proper medical management of confirmed endometriosis — they support symptom management alongside it. If you have severe menstrual pain that affects daily function, painful intercourse, infertility, or pelvic pain that doesn''t respond to over-the-counter pain relief — please see a gynecologist who specifically treats endometriosis. Many general OBs miss it.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Turmeric, ground (1 tsp) | ~60 to 200 mg curcuminoids | — |
| Fresh turmeric root (1 inch) | ~60 to 100 mg curcuminoids | — |
| Curry powder (1 tsp) | ~50 to 100 mg curcuminoids | — |
Turmeric, ground (1 tsp)
- Amount
- ~60 to 200 mg curcuminoids
- %DV
- —
Fresh turmeric root (1 inch)
- Amount
- ~60 to 100 mg curcuminoids
- %DV
- —
Curry powder (1 tsp)
- Amount
- ~50 to 100 mg curcuminoids
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Why is curcumin absorption so poor?⌄
Curcumin is rapidly conjugated (glucuronidation, sulfation) in the gut and liver, then excreted. The result is that plain curcumin reaches plasma at very low concentrations. Piperine blocks the conjugation enzymes, raising absorption substantially. Specialized formulations like liposomal or phytosomal curcumin go further by improving uptake and stability.
Is BCM-95 or Meriva better?⌄
Both are well-studied and effective. BCM-95 uses natural turmeric essential oils for absorption enhancement; Meriva uses a phosphatidylcholine complex. Both achieve substantially higher plasma curcumin than plain extract. Choice often comes down to availability and cost rather than meaningful efficacy differences.
How long until I notice effects?⌄
For osteoarthritis pain, meaningful effects typically build over 4 to 8 weeks. For inflammation markers, blood tests show changes over similar timeframes. Don't expect acute relief from a single dose.
Can I take curcumin with my arthritis medication?⌄
Coordinate with your prescriber. Curcumin combined with NSAIDs may increase GI and bleeding risks. With biologics and DMARDs, the interaction profile is less well characterized but immune-modulating effects could theoretically interact.
Is curcumin safe long-term?⌄
Doses up to 8 grams per day have been studied short-term without major safety signals. Long-term high-dose use, especially with high-bioavailability formulations, has been linked to rare cases of liver injury. Conservative practice is to cycle or take periodic breaks; consult a clinician if you use it daily for years.
References by claim
osteoarthritis pain and function
inflammatory biomarkers (CRP, IL-6)
Gorabi et al., 2022 — PubMed (2022) link
depression (adjunct treatment)
Track Curcumin with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.